- The company was recognized for its strong performance in Small Molecule API development and manufacturing.
- This first edition of the European award highlights excellence validated directly by customers and an independent expert jury.
AGC Pharma Chemicals, a global CDMO specializing in Active Pharmaceutical Ingredients (APIs) and Highly Potent APIs (HPAPIs), with facilities in Barcelona, Spain, and Japan, has been honored as Champion in Small Molecule API at the European CDMO Leadership Awards 2025, announced during CPHI Frankfurt 2025.
This recognition is especially meaningful as it is based on direct customer evaluations and independent expert assessment, with a fully objective process and no participation fees.
Earlier this year, AGC Pharma Chemicals was also awarded at the global CDMO Leadership Awards 2025 in the category Best Manufacturing Capabilities, reinforcing its strong position and reputation in the market.
Jun Kurihara, CEO of AGC Pharma Chemicals, stated: “We are extremely proud to receive this European recognition, especially because it reflects the trust and positive evaluations from our customers. Our commitment to quality and innovation is at the core of what we do, and this award motivates us to continue growing alongside our partners. My heartfelt congratulations to our amazing team: they make achievements like this possible.”
AGC Pharma Chemicals continues to advance its operations through strategic investments in advanced technologies, including new API and HPAPI capabilities with OEB4 and OEB5 containment, and a strong focus on process excellence.
This award further strengthens the company’s role as a trusted CDMO partner in delivering high-quality solutions that support the development of innovative therapies worldwide.
